Evidence of miR‐153‐3p association with Alzheimer's disease (AD) and the mechanism of miR‐153‐3p on critical proteins suggest a therapeutic and biomarker potential of miR‐153‐3p in AD and related dementias
With the increased emphasis on comorbidities of AD and other neurodegenerative diseases, we identified that miR-153-3p, as a master regulator, reduced a key group of neurodegeneration-related proteins. MiR-153-3p reduces APP, SNCA and REST expression, all pointing towards a therapeutic and biomarker potential in ADRDs. In addition to late-onset cases, we will profile miR153 in brain tissue samples from early-onset AD cases.
Authors
- B. Ghetti
- Bryan Maloney (ORCID: https://orcid.org/0000-0003-2364-9649)
- Kumar Sambamurti (ORCID: https://orcid.org/0000-0001-9507-9214)
- Scott Counts (ORCID: https://orcid.org/0000-0003-2851-9763)
- Fletcher A. White (ORCID: https://orcid.org/0000-0002-8408-9262)
- Ruizhi Wang (ORCID: https://orcid.org/0009-0008-8215-3524)
- Andrew Joel Saykin
- Kwangsik Nho
- Martin R. Farlow
- Debomoy K. Lahiri
Institutions
- Medical University of South Carolina (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Michigan State University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_100551
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00